Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma
NCT02339558Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jul 2015
- Primary completion
- Jun 2018
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
A Phase 2 trial of nivolumab in nasopharyngeal carcinoma (NPC), sponsored by National Cancer Institute. Started Jul 2015; status: completed.
02
Drugs
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT02339558.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02339558.